Dear Editor,Accumulating evidence suggests that dysregulated lysosomal membrane proteins,including vacuolar ATPase(v-ATPase)and the mammalian target of rapamycin(mTOR),are involved in tumorigenesis[1].Therefore,lysoso...Dear Editor,Accumulating evidence suggests that dysregulated lysosomal membrane proteins,including vacuolar ATPase(v-ATPase)and the mammalian target of rapamycin(mTOR),are involved in tumorigenesis[1].Therefore,lysosomal proteins were proposed as potential therapeutic targets in cancer[1].As one of the lysosome-related signaling pathways,mTOR signaling regulates cell proliferation,survival,motility,and metabolism[2].SincemTOR signaling activation promotes tumorigenesis,mTOR inhibitors(mTORi),AZD8055[3],MLN0128[4],and Rapalink-1(the latest third-generation mTORi)[4],have been applied to several cancers.However,the limitations of mTORi include drug resistance and the lack of biomarkers.展开更多
文摘Dear Editor,Accumulating evidence suggests that dysregulated lysosomal membrane proteins,including vacuolar ATPase(v-ATPase)and the mammalian target of rapamycin(mTOR),are involved in tumorigenesis[1].Therefore,lysosomal proteins were proposed as potential therapeutic targets in cancer[1].As one of the lysosome-related signaling pathways,mTOR signaling regulates cell proliferation,survival,motility,and metabolism[2].SincemTOR signaling activation promotes tumorigenesis,mTOR inhibitors(mTORi),AZD8055[3],MLN0128[4],and Rapalink-1(the latest third-generation mTORi)[4],have been applied to several cancers.However,the limitations of mTORi include drug resistance and the lack of biomarkers.
